OncoMatch/Clinical Trials/NCT06481592
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
Is NCT06481592 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Lifileucel for endometrial cancer.
Treatment: Lifileucel — The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Endometrial Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy
Must have received: anti-pd-1/pd-l1 therapy
Lab requirements
Cardiac function
adequate cardiopulmonary function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Honor Health · Phoenix, Arizona
- University of Southern California · Los Angeles, California
- Orlando Health · Orlando, Florida
- H. Lee Moffitt Cancer Center and Research Institute, Inc. · Tampa, Florida
- Augusta University · Augusta, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06481592 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received platinum-based chemotherapy and anti-pd-1/pd-l1 therapy.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages